MidWestOne Financial Group Inc. Has $1.34 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

MidWestOne Financial Group Inc. increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 42.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,805 shares of the medical research company's stock after purchasing an additional 2,019 shares during the quarter. MidWestOne Financial Group Inc.'s holdings in IQVIA were worth $1,337,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Synergy Asset Management LLC bought a new stake in IQVIA during the 4th quarter worth about $33,000. GKV Capital Management Co. Inc. acquired a new stake in IQVIA in the 4th quarter valued at about $39,000. Lee Danner & Bass Inc. acquired a new stake in IQVIA in the 4th quarter valued at about $44,000. Zions Bancorporation N.A. increased its position in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in IQVIA in the 4th quarter valued at about $60,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

IQV has been the subject of several research reports. Truist Financial lowered their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. UBS Group reduced their target price on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, Stifel Nicolaus reduced their target price on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $228.14.

IQVIA Stock Down 0.8%

IQV stock traded down $1.08 during mid-day trading on Friday, hitting $136.96. 2,248,506 shares of the company were exchanged, compared to its average volume of 1,556,967. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market cap of $23.69 billion, a P/E ratio of 18.26, a P/E/G ratio of 1.99 and a beta of 1.34. The firm's 50 day simple moving average is $155.33 and its 200 day simple moving average is $183.63. IQVIA Holdings Inc. has a 1-year low of $134.02 and a 1-year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same period last year, the company earned $2.54 earnings per share. The firm's revenue was up 2.5% compared to the same quarter last year. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.